News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
119,850 Results
Type
Article (7160)
Company Profile (56)
Press Release (112634)
Section
Business (38196)
Career Advice (87)
Deals (5916)
Drug Delivery (8)
Drug Development (23653)
Employer Resources (12)
FDA (2982)
Job Trends (3560)
News (68682)
Policy (4596)
Tag
Academia (320)
Africa (81)
Alabama (18)
Alliances (11083)
Alzheimer's disease (111)
Antibody-drug conjugate (ADC) (45)
Approvals (2978)
Artificial intelligence (26)
Asia (10265)
Australia (1361)
Bankruptcy (53)
Best Places to Work (3180)
Biosimilars (15)
Biotechnology (48)
Bladder cancer (14)
Breast cancer (50)
C2C Services and Suppliers (7257)
California (576)
Canada (194)
Cancer (439)
Career advice (74)
CAR-T (29)
Cell therapy (60)
China (73)
Clinical research (19118)
Collaboration (71)
Colorado (16)
Compensation (22)
Connecticut (23)
COVID-19 (296)
C-suite (12)
Data (190)
Delaware (29)
Diagnostics (1229)
Drug discovery (15)
Earnings (12463)
Europe (18931)
Events (22226)
Executive appointments (59)
FDA (3063)
Florida (72)
Funding (39)
Gene therapy (18)
GLP-1 (91)
Government (460)
Healthcare (4022)
Hotbed/Location (82784)
Illinois (50)
Indiana (19)
Infectious disease (305)
Inflammatory bowel disease (18)
IPO (2918)
Japan (18)
Job creations (482)
Job search strategy (70)
Layoffs (108)
Legal (467)
Liver cancer (30)
Lung cancer (104)
Lymphoma (13)
Maryland (114)
Massachusetts (513)
Medical device (833)
Medtech (833)
Mergers & acquisitions (2992)
Metabolic disorders (24)
Minnesota (46)
Neuroscience (137)
New Jersey (129)
New York (150)
NextGen Class of 2024 (943)
Non-profit (488)
North Carolina (123)
Northern California (276)
Ohio (26)
Opinion (24)
Ovarian cancer (22)
Pancreatic cancer (16)
Pennsylvania (100)
People (12529)
Phase I (7171)
Phase II (8072)
Phase III (6140)
Pipeline (52)
Postmarket research (470)
Preclinical (2198)
Prostate cancer (23)
Radiopharmaceuticals (153)
Real estate (729)
Regulatory (3895)
Research institute (659)
Series A (13)
South America (111)
Southern California (245)
Startups (751)
Texas (71)
United States (2175)
Utah (13)
Vaccines (85)
Washington State (58)
Date
Today (19)
Last 7 days (162)
Last 30 days (785)
Last 365 days (9951)
2024 (7346)
2023 (10638)
2022 (13112)
2021 (13176)
2020 (10961)
2019 (8592)
2018 (6333)
2017 (7123)
2016 (6284)
2015 (6949)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3038)
119,850 Results for "istari oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
Istari Oncology, Inc. today announced the first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the LUMINOS-103 basket trial.
January 31, 2023
·
3 min read
Bio NC
Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress
Istari Oncology today announced a poster presentation of new data from an enhanced dosing cohort within the LUMINOS-102 phase 2 clinical trial, which is assessing the safety and efficacy of lerapolturev (formerly PVSRIPO) alone or in combination with a programmed death receptor-1 (PD-1) inhibitor in patients with metastatic melanoma who have progressed on an anti-PD-1 containing regimen, and BRAF/MEK inhibitors if BRAF mutation positive.
October 18, 2022
·
5 min read
BioCapital
Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)
Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)
November 9, 2021
·
4 min read
Business
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.
June 10, 2024
·
3 min read
Bio NC
Istari Oncology to Participate in Upcoming Virtual Investor Conferences in September 2021
Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, announced the company will participate in the following two virtual investment conferences taking place in September 2021:
September 7, 2021
·
1 min read
Drug Development
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
September 30, 2024
·
7 min read
Bio NC
First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
Istari Oncology, Inc. today announced its first patient was dosed in the company’s LUMINOS-103 bladder cancer sub-study (NCT04690699).
October 12, 2021
·
5 min read
Cancer
ESMO 2024 Preview: Bispecifics and TIGITs Among the Hottest Topics in Oncology
Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand therapies and synthetic lethality assets are also attracting attention.
September 9, 2024
·
4 min read
·
Heather McKenzie
Business
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team
Istari Oncology, Inc. today announced that Jamie Iudica has joined as Chief Manufacturing Officer (CMO).
June 8, 2021
·
2 min read
Biotech Beach
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology, Inc. today announced its participation in Stifel 2024 Targeted Oncology Forum.
April 10, 2024
·
2 min read
1 of 11,985
Next